CLINICAL_TRIALS
trial_result
· 2010-02-19
Clinical Trial Update: Study of XL999 in Patients With Metastatic Renal Cell Carcinoma [Phase 2]
Summary
A Phase 2 study of XL999 in metastatic renal cell carcinoma has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Symphony Evolution, Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED